SCHEMBL868638

SCHEMBL868638

CCC(=O)CCC(N)=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30381889 0.97 TDP1 (0.47)
SCHEMBL7769250 0.86 TDP1 (0.47)
SCHEMBL29602724 0.86 TDP1 (0.47)
SCHEMBL619312 0.84 TDP1 (0.69)
SCHEMBL30361025 0.83 KMT2A (0.50)
SCHEMBL28315001 0.83 KMT2A (0.50)
SCHEMBL30693097 0.81 TDP1 (0.43)
SCHEMBL14586286 0.81
SCHEMBL7086753 0.81 ALOX15 (0.46)
SCHEMBL8984748 0.81 TDP1 (0.64)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1888595-A2 SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2008-02-20 EP claimed
WO-2006110917-A2 SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2006-10-19 WO claimed
EP-3606560-A2 OLIGOMER EXTENDED INSULIN-FC CONJUGATES Novo Nordisk A/S (DK) 2020-02-12 EP disclosed
CN-105792852-B Glucose-responsive insulin conjugates 默沙东公司 2019-12-10 CN disclosed
WO-2018185131-A2 OLIGOMER EXTENDED INSULIN-FC CONJUGATES NOVO NORDISK A/S (DK) 2018-10-11 WO disclosed
US-20180092915-A1 SODIUM CHANNEL BLOCKERS FOR SKIN DISORDERS PARION SCIENCES, INC. (US) 2018-04-05 US disclosed
US-20170043024-A1 BIOACTIVE CONJUGATES FOR OLIGONUCLEOTIDE DELIVERY UNIVERSITY OF MASSACHUSETTS 2017-02-16 US disclosed
CN-104357676-B The method extracting lithium in salt lake bittern 中国科学院青海盐湖研究所 2016-10-12 CN disclosed
US-9314026-B2 Heterocyclylpyri(mi)dinylpyrazole BAYER INTELLECTUAL PROPERTY GMBH (DE) 2016-04-19 US disclosed
WO-2015168514-A1 METHOD FOR SYNTHESIS OF REACTIVE CONJUGATE CLUSTERS ISIS PHARMACEUTICALS, INC. (US) 2015-11-05 WO disclosed
WO-2015168532-A2 COMPOSITIONS AND METHODS FOR MODULATING PKK EXPRESSION ISIS PHARMACEUTICALS, INC. (US) 2015-11-05 WO disclosed
US-20070244172-A1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS WELLSTAT THERAPEUTICS CORPORATION (US) 2007-10-18 US disclosed
US-20070155730-A1 Benzodiazepine And Benzopiperazine Analog Inhibitors Of Histone Deacetylase METHYLGENE, INC. (CA) 2007-07-05 US disclosed
US-20070105958-A1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS WELLSTAT THERAPEUTICS CORPORATION (US) 2007-05-10 US disclosed
US-20070105958-A1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS WELLSTAT THERAPEUTICS CORPORATION (US) 2007-05-10 US disclosed
EP-1613626-A1 CYCLIC BENZIMIDAZOLES ALTANA Pharma AG (DE) 2006-01-11 EP disclosed
WO-2004087701-A1 CYCLIC BENZIMIDAZOLES ALTANA PHARMA AG (DE) 2004-10-14 WO disclosed
EP-0765879-B1 13-Substituted milbemycin 5-oxime derivatives, their preparation and their use against insects and other pests SANKYO CO (JP) 2001-02-14 EP disclosed
US-5861429-A MITICIDES AND ANTHELMINTICS SANKYO COMPANY, LIMITED (JP) 1999-01-19 US disclosed
EP-0765879-A1 13-Substituted milbemycin 5-oxime derivatives, their preparation and their use against insects and other pests SANKYO COMPANY LIMITED (JP) 1997-04-02 EP disclosed